Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.68 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.68 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31444687 | 0.95 | CRBN (0.62) | CRBNDDB1GPR119STAT3GSPT1 | |
| SCHEMBL30805411 | 0.95 | CRBN (0.66) | CRBNDDB1GPR119STAT3GSPT1 | |
| SCHEMBL20234428 | 0.92 | DDB1 (0.72) | CRBNDDB1GPR119STAT3GSPT1 | |
| SCHEMBL21997637 | 0.91 | CRBN (0.63) | CRBNDDB1GPR119STAT3GSPT1 | |
| SCHEMBL30805376 | 0.91 | DDB1 (0.70) | CRBNDDB1GPR119STAT3 | |
| SCHEMBL22836481 | 0.89 | CRBN (0.65) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL20325482 | 0.88 | DDB1 (0.73) | CRBNDDB1GPR119STAT3GSPT1 | |
| SCHEMBL24822626 | 0.87 | CRBN (0.79) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL28881342 | 0.87 | CRBN (0.69) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL21069262 | 0.87 | CRBN (0.63) | CRBNDDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035356-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025094065-A1 | AMINO-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-05-08 | — | — | WO | disclosed |
| WO-2024020221-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2023066363-A1 | PARP-1 DEGRADATION AGENT AND USE THEREOF | 海思科医药集团股份有限公司 | 2023-04-27 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035356-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | TYK2, CRBN, CSNK2A3 | CRBN 2/4885DDB1 1322/4885GPR119 4253/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885GPR119 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.